Current Projects

International

IMPROVE – 3Rs concepts to improve the quality of biomedical science (IMPROVE)
3Rs concepts to improve the quality of biomedical science (IMPROVE)
Program: COST
Project leader: Dr.rer.nat., Ing. Kanďárová Helena, ERT
Project web page: https://www.cost.eu/actions/CA21139/
Duration: 1.8.2022 –
NETSKINMODELS – European Network for Skin Engineering and Modeling (NETSKINMODELS)
Engineering novel 3D organotypic skin models
Program: COST
Project leader: Dr.rer.nat., Ing. Kanďárová Helena, ERT
Project web page: https://www.cost.eu/actions/CA21108/
Duration: 1.5.2022 –
ONTOX – Testovanie opakovanej toxicity chemických látok na základe ontológie a umelej inteligencie za účelom hodnotenia rizík metódami NGRA
Ontology-driven and artificial intelligence-based repeated dose toxicity testing of chemicals for next generation risk assessment
Program: Horizon 2020
Project leader: Dr.rer.nat., Ing. Kanďárová Helena, ERT
Annotation: The vision of the ONTOX project is to provide a functional and sustainable solution for advancing human risk assessment of chemicals without the use of animals in line with the principles of 21st century toxicity testing and next-generation risk assessment. Specifically, ONTOX will deliver a generic strategy to create innovative new approach methodologies (NAMs) in order to predict systemic repeated dose toxicity effects that, upon the combination with tailored exposure assessment, will enable human risk assessment. This strategy can be applied to any type of chemical and systemic repeated dose toxicity effect. However, for proof-of-concept purposes, focus will be put on 6 specific NAMs addressing adversities in the liver (steatosis and cholestasis), kidneys (tubular necrosis and crystallopathy) and developing brain (neural tube closure and cognitive function defects) induced by a variety of chemicals, including from the pharmaceutical, cosmetics, food and biocide sectors. The 6 NAMs will each consist of a computational system based on cutting-edge artificial intelligence (AI) and will be primarily fed by available biological/mechanistic, toxicological/ epidemiological, physico-chemical and kinetic data. Data will be consecutively integrated in physiological maps, quantitative adverse outcome pathway networks and ontology frameworks. Data gaps, as identified by AI, will be filled by targeted state-of-the-art in vitro and in silico testing. The 6 NAMs will be evaluated and applied in collaboration with industrial and regulatory stakeholders in order to maximise end-user acceptance and regulatory confidence. This is anticipated to expedite implementation in risk assessment practice and to facilitate commercialisation. ONTOX will have a deep and long-lasting impact at many levels, in particular by consolidating Europe\’s world-leading position regarding the development, exploitation, regulation and application of animal-free methods for human risk assessment of chemicals.
Project web page: www.ontox-project.eu
Duration: 1.5.2021 – 1.5.2026
BenBedPhar – Bench to bedside transition for pharmacological regulation of NRF2 in noncommunicable diseases
Bench to bedside transition for pharmacological regulation of NRF2 in noncommunicable diseases
Program: COST
Project leader: RNDr. Bernátová Iveta, DrSc.
Annotation: Non-communicable diseases (NCDs) such as cancer, diabetes, cardiovascular, neurodegenerative, respiratory or immune diseases, account for 77% of all deaths in Europe and remain the most prevalent and without effective therapy. Networking among multidisciplinary teams that explore disease from a perspective of causative pathomechanisms rather than clinical symptoms is the most appropriate approach to overcome this problem. Such pathomechanisms imply the loss of homeostatic functions leading to the pathologic formation of reactive oxygen species, chronic inflammation, metabolic unbalance and proteinopathy. The transcription factor NRF2 is a master regulator of multiple cytoprotective responses and a key molecular link among many NCDs. It provides a unique strategy for drug development and repurposing that is now starting to be translated to the pharmacological and clinical arena. This Action build a network of excellence for integrating and spreading the existing knowledge and providing innovative services, drugs and tools related to NRF2-pharmacology, with the final goal of boosting the translation to the European industry sector. To achieve this, the Action has already gathered a wide set of professionals from different disciplines (medical chemistry, pharmacology, clinical research, molecular biology, bioinformatics, etc.) and sectors (universities, research centres, hospitals, biobanks, biotech and pharma companies, etc.). Thanks to COST tools the Action will boost the career of young researchers, wide participation, and spread excellence.
Duration: 19.10.2021 – 18.10.2025
EU-NETVAL Medzinárodná validačná štúdia tyroidnej disrupcie
EU-NETVAL International Thyroid Validation Study
Program: Multilateral – other
Project leader: Dr.rer.nat., Ing. Kanďárová Helena, ERT
Annotation: Characterising, validating and standardising new non-animal methods and approaches are important steps towards their regulatory use and international adoption. Various thyroid methods, targeting different modes of action of thyroid disruption, are currently under validation by EURL ECVAM and its network of validation laboratories EU-NETVAL. Chemicals that disrupt thyroid homeostasis have the potential to be endocrine disruptors and thus associated with several adverse health effects.About EU-NETVAL:EU-NETVAL is a large network of 39 highly qualified test facilities across Europe, coordinated by the JRC to support the in vitro method validation process. It represents a wide range of expertise and competences and includes laboratories experienced in advanced in vitro procedures, biological test systems and measurement techniques.
Project web page: https://ec.europa.eu/jrc/en/eurl/ecvam/alternative-methods-toxicity-testing/eu-netval
Duration: 1.1.2021 – 1.1.2023
Protizápalový účinok prírodných látok izolovaných z vietnamských liečivých rastlín
Anti-inflammatory effects of natural compounds isolated from Vietnam medicinal plants
Program: Bilateral – other
Project leader: PharmDr. Bauerová Katarína, PhD., DrSc.
Duration: 1.1.2020 – 31.12.2022
Protizápalový účinok prírodných látok izolovaných z vietnamských liečivých rastlín
Anti-inflammatory effects of natural compounds isolated from Vietnam medicinal plants
Program: Bilateral – other
Project leader: PharmDr. Bauerová Katarína, PhD., DrSc.
Duration: 1.4.2020 – 31.12.2022
SKPTPHARMACOL – Spolupráca na komplexnom hodnotení farmakologického ovplyvnenia zápalových ochorení pohybového aparátu a gastrointestinálneho traktu na experimentálnych zvieracích modeloch
Collaboration on a complex pharmacological assessment of inflammatory diseases of the musculo-skeletal system and gastrointestinal tract on experimental animal models
Program: Bilateral – other
Project leader: PharmDr. Bauerová Katarína, PhD., DrSc.
Annotation: Animal models have been used to study inflammatory diseases for almost a century. Our innovative approach in the research of inflammation and autoimmunity of the musculoskeletal and gastrointestinal tract is to use simultaneously multiple experimental models with well-known pathophysiology (i.e.: Collagen type-II-induced arthritis, Adjuvant-induced arthritis, Carrageenan induced oedema and trinitrobenzenesulfonic acid induced colitis). This enables us to better understand and describe the pharmacodynamic mode of action of experimental treatments approximately to human disease. Selected active substances studied on several models mentioned above, can bring us to deeper elucidation of mechanism of action. Moreover, the combination of substances studied together with an appropriate disease modifying anti-rheumatic drug may improve the standard treatment of inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel disease. The main outputs of this project will be to meet on our workplaces, sharing methodology and results analysis to create the proposal for future cooperation in between Slovakia and Portugal. In parallel we also plan to manage two bilateral conferences and to engage our PhD students and post-docs to this project. During the duration of this project we will seek for possibilities how to be a part of a multilateral and EU project network.
Duration: 1.1.2019 – 31.12.2022
Train -SafeMDs – Školiaca sieť zameraná na zvýšenie bezpečnosti zdravotníckych pomôcok – fokus na ústnu dutinu
Training Network for improving of safety of medical devices – focus on oral cavity
Program: Multilateral – other
Project leader: Dr.rer.nat., Ing. Kanďárová Helena, ERT
Annotation: The TraiN-SafeMDs (i.e. Training Network for improving knowledge on the safety of medical devices) project brings together the unique expertise of the Czech National Institute of Public Health located in Prague (NIPH), the expertise of the Centre of Experimental Medicine in Bratislava (CEM) and the Austrian Institute of Technology in Vienna (AIT). The research team of the project has extensive expertise in tissue engineering of models of oral epithelium and/or in safety testing of different MD materials. The project also aims into the training of PhD students and early career scientist in the use of in vitro methods for the safety assessment of MDs.
Project web page: https://www.medicaldevicessafety.com/
Duration: 1.1.2020 – 31.12.2022
LOGIC LAB – Molecular logic lab-on-a-vesicle for intracellular diagnostics
Molecular logic lab-on-a-vesicle for intracellular diagnostics
Program: Horizon 2020
Project leader: RNDr. Mach Mojmír, PhD.
Annotation: A dysfunction of cells lining the inner walls of blood vessels, i.e. the endothelium, is the primary cause of many lifestyle related diseases. According to the WHO, those diseases accounted for 60% of all deaths worldwide in 2005. Tailor-made diagnostic tools for early and reliable identification of endothelial dysfunction are urgently needed both in fundamental research and clinical routine, respectively.The Marie Skłodowska-Curie action LOGIC LAB objects to develop and characterize innovative molecular logic gates that can be applied as advanced diagnostic tools for parallel analyte sensing in live mammalian cells. Thereby, providing a unique method to discover endothelial dysfunction and the onset of diseases much easier and earlier than so far.LOGIC LAB creates a multi-faceted and multi-sectoral research environment for the next generation of scientists in order to establish a novel type of molecular logic sensors that reliably operate in biological media – a crucial requirement for their application i.e. as rapid and easy-to-handle tools for intracellular diagnostics.With excellent cross-disciplinary scientific and complementary training provided in the network, we aim to educate highly-skilled young scientists in the fields of chemistry, physics and biology, who will significantly strengthen the international research community in the domain of molecular logic sensing. Thus, in the long term, LOGIC LAB aims to finally bridge the gap between lab bench and biological or medical practice. It is this gap, that so far prevents a wide-ranging use of existing molecular logic gates e.g. for the diagnosis of lifestyle-associated diseases.
Duration: 1.11.2018 – 31.10.2022
CardioRNA – Katalýza transkriptomického výskumu kardiovaskulárnych ochorení
Catalysing transcriptomic research in cardiovascular disease
Program: COST
Project leader: doc. RNDr. Barteková Monika, PhD.
Duration: 3.10.2018 – 2.10.2022

National

Ligandom podmienená modulácia vápnikovej pumpy – štúdium mechanizmu a návrh nových látok
Ligand induced modulation of calcium pump SERCA – study of mechanism and design of new compounds
Program: VEGA
Project leader: RNDr. Májeková Magdaléna, PhD.
Annotation: Calcium signaling plays a crucial role in many physiological processes such as muscle contraction, gene expression, apoptosis and insulin secretion. A primary role in the maintenance of intracellular Ca2+ concentration belongs to SERCA – sarco/endoplasmic reticulum Ca2+-ATPase. As an impaired function of Ca2+-ATPase is associated with various chronic diseases and disorder, the compounds able to restore it are important as potential drugs. Our aim is to elucidate the mechanism of known SERCA activators by means of experimental and theoretical methods and to use this knowledge in design of new compounds, able to maintain SERCA function. In the framework of our research related to diabetes, we plan to include two more targets in our design – inhibition of polyol pathway and oxidation stress.
Duration: 1.1.2022 – 31.12.2026
SUFIBAR – Cielená supresia pro-zápalových a pro-fibrotických signálnych dráh pre zabránenie život ohrozujúceho zlyhávania srdca a výskytu malígnych arytmií
Targeted suppression of pro-inflammatory and pro-fibrotic signaling pathways to prevent heart failure and occurrence of malignant arrhythmias
Program: SRDA
Project leader: RNDr. Szeiffová Bačová Barbara, PhD.
Annotation: Heart failure is characterized by a progressive reduction in cardiac output and occurrence of malignant arrhythmias resulting in substantial morbidity and mortality worldwide. Cardiac fibrosis, the key factor contributing to these life-threatening events, is still unresolved problem in clinic. Detection and management of myocardial fibrosis suffer from a lack of precision, therefore, novel approaches are extremely needed. We hypothesize that the determination of myocardial fibrosis phenotypes in a disease-specific way may reveal more precisely molecular targets for efficient prevention and/or treatment. The idea of the project is to differentiate myocardial fibrosis phenotypes via assessment of circulating markers of oxidative stress, inflammation and pro-fibrotic components along with determining the activation of actual signaling pathways and extent of fibrosis. In the same time to explore efficacy of selected compounds, AT1 receptor blocker, ACE inhibitor, melatonin, triiodothyronine, metoprolol, omega-3 fatty acids and molecular hydrogen, to suppress pro-inflammatory and pro-fibrotic signaling pathways including purinergic signaling mediated by connexin-43 hemichannels and panexin-1 channels and to prevent or attenuate adverse structural and electrical remodeling. Novel findings may provide fundamental input to targeted therapy aimed to reduce myocardial fibrosis burden and challenge to realize well designed clinical trials.
Duration: 1.7.2022 – 30.6.2026
CARDIOPROT – Nové aspekty kardioprotekcie prírodnými antioxidantami: vplyv starnutia a komorbidít súvisiacich so životným štýlom
New aspects of cardioprotection by natural antioxidants: role of ageing and lifestyle-related comorbidities
Program: SRDA
Project leader: doc. RNDr. Barteková Monika, PhD.
Annotation: Despite the important progress in the treatment of cardiovascular disease (CVD), the new therapeutic strategies as well as mechanisms involved are still being extensively studied to reach the optimal efficiency of the therapy. Ischemia/reperfusion (I/R) injury represents a clinically relevant problem associated with CVD (including ischemic heart disease and myocardial infarction) as well as with cardiac surgery. Natural antioxidants including flavonoid quercetin and several catechins have been shown to exert protective effects against cardiac I/R injury. However, most of the experimental studies have been performed in young healthy animals what is not corresponding to the situation in real life where the patients prone to acute ischemic event (myocardial infarction) are usually aged people suffering from some comorbidities such as hypertension or metabolic disorders. Thus the aim of the current project is to reveal the real therapeutic potential of selected natural antioxidants, quercetin and epicatechin against cardiac I/R injury in aged subjects and subjects suffering from selected metabolic comorbidities (type 2 diabetes, hypertriglyceridemia) and hypertension. Another goal of the project is to uncover intra- as well as intercellular mechanisms involved in the action of selected antioxidantss in individuals with comorbidities exposed to cardiac I/R, including their interactions with mechanisms involved in development of selected comorbidities. Meeting the objectives of the project will significantly help to better management of patients suffering from CVD, particularly from acute myocardial infarction
Duration: 1.7.2022 – 30.6.2026
Inhibítory aldo-keto reduktáz v personalizovanej liečbe viacerých typov rakoviny
Aldo-keto reductase inhibitors in the personalized therapy of several types of cancer
Program: VEGA
Project leader: Ing. Šoltésová Prnová Marta, PhD.
Duration: 1.1.2022 – 31.12.2025
Môže byť modulácia sarko/endoplazmatickej Ca2+ – ATPázy (SERCA) vybranými prírodnými látkami regulovaná sirtuínmi? Význam v podpornej liečbe diabetických komplikácií a nádorových ochorení.
Program: VEGA
Project leader: Mgr. Heger Vladimír, PhD.
Duration: 1.1.2022 – 31.12.2025
Nové metódy liečby srdcového zlyhania. Prevencia oxidačného stresu molekulárnym vodíkom.
New methods of treating heart failure. Prevention of oxidative stress by molecular hydrogen.
Program: VEGA
Project leader: RNDr. Kura Branislav, PhD.
Annotation: Heart failure (HF) globally affects approximately 26 million people worldwide. Despite many therapeutic advances in the symptomatic treatment of HF, the prevalence, mortality and costs associated with treatment in developed countries continue. One of the key mechanisms involved in the development of the pathophysiology of the failing heart is the uncontrolled overproduction of reactive oxygen species, which causes damage to lipids in membranes, mitochondria, proteins and DNA, leading to cell death. Blocking hydroxyl and nitrosyl radicals could therefore prevent the destruction of cellular components and the progression of HF.Recently, it was discovered that molecular hydrogen (H2) has a protective effect in the case of damage to various organs, mainly due to its antioxidant activity. We hypothesize that H2 application could be a new effective treatment for HF patients. The project is aimed at investigating the therapeutic use of H2 and its ability to act cardioprotectively in the isoproterenol-induced HF model in older rats.
Duration: 1.1.2022 – 31.12.2025
Vývoj diabetickej nefropatie a jej liečba nutraceutikom v experimentálnych podmienkach
Development of diabetic nephropathy and its treatment with nutraceutic in experimental conditions
Program: VEGA
Project leader: Mgr. Kaločayová Barbora, PhD.
Duration: 1.1.2022 – 31.12.2025
Vývoj multifunkčných inhibítorov aldózareduktázy na báze triazínoindolov: Optimalizácia ich biologickej aktivity, selektivity, biodostupnosti a antioxidačných vlastností.
Development of multifunctional aldose reductase inhibitors based on triazinoindoles: Optimization of their biological activity, selectivity, bioavailability and antioxidant properties.
Program: VEGA
Project leader: RNDr. Kováčiková Lucia, PhD.
Duration: 1.1.2022 – 31.12.2025
ACE2MAS – Kardiometabolické účinky stimulácie Mas receptorov modulovaním renín-angiotenzínového systému – klúčová úloha angiotenzínkonvertujúceho enzýmu 2.
Cardiometabolic effects of Mas receptor stimulation by modulation of the renin-angiotensin system – the key role of angiotensin-converting enzyme 2
Program: SRDA
Project leader: RNDr. Čačányiová Soňa, PhD.
Annotation: The renin-angiotensin system (RAS) is a hormonal cascade whose chronic activation contributes to the development of cardiovascular pathologies caused mainly by remodeling of the heart and blood vessels. It is becoming apparent that the benefit of RAS inhibitors includes, in addition to Ang II inhibition, stimulation of the alternative arm of RAS mediated by the ACE2/Ang1-7/Mas receptor, which has vasodilatory, antiproliferative, antiinflammatory and metabolic effects. The aim of the present project will be to compare the effect of ACE inhibition, AT1 blockade, stimulation of ACE2 (diminazene) and Mas receptor (cyclic Ang1-7, alamandine) in a model of old, obese, diabetic hypertensive Zucker rats with a focus on the potential benefit of Ang1-7/Ang1-5 on glucose utilization, insulin signal transduction, reduction of the inflammatory response and function of the cardiovascular system. Given the potentially key role of RAS and especially ACE2 in the development of acute respiratory distress syndrome (ARDS) and the severe course of COVID-19, the aim of the present project will be to detect changes in membrane and serum ACE2 and expression of other key molecules for viral infection (ADAM17, TMPRSS2, furin and B0AT1 transporter) using various pharmacological interventions. The dependence of the putative alterations on the activity of the Mas receptor will be monitored by its specific antagonist A779. In vitro, following treatment of human alveolar cells and adipocyte cultures with RAS and diminazene inhibitors, the changes in the ability to bind SARS-CoV-2 virus will be assessed using a pseudoviral methodology. The obtained results might contribute to the elucidation of the role of ACE2 and Mas receptor in the pathogenesis of obesity and diabetes. The project might also contribute to the clarification of the choice of an effective RAS inhibitor in the elderly with a combination of hypertension, obesity and diabetes.
Duration: 1.7.2021 – 30.6.2025
StrokeRehab – Nový prístup k rehabilitácii pacientov po cievnej mozgovej príhode. Základný a translačný výskum s cieľom zlepšiť funkciu rovnováhy a symetriu tela u pacientov po cievnej mozgovej príhode pomocou senzorickej stimulácie.
Novel approach to post-stroke rehabilitation. A basic and translational study, aiming to restore posture control and body symmetry in post-stroke patients by sensory stimulation.
Program: SRDA
Project leader: RNDr. Bzdúšková Diana, PhD.
Annotation: The main goal of this project is to investigate the pathophysiological mechanisms of keeping balance while sitting and standing in post-stroke patients and to define the rationale for interventions based on visual and proprioceptive stimulations for enhancing balance, impaired trunk mobility and trunk asymmetry. To achieve this, we will use the original method for rehabilitation and monitoring of patients as well as specialized devices together with softwares which we developed during our previous project APVV-16-0233. Stroke is a major health problem, especially considering that post-stroke patients typically have residual impairments to their motor and sensory functions directly affecting their postural system. Keeping balance while sitting up in bed or on a chair is with high probability the first thing a therapist addresses to patients. Controlled trunk function is an important and essential component for standing balance, gait and other daily activities. The voluntary movements of the trunk clearly reveal the postural and movement asymmetry of the upper part of the body. The asymmetric position is most often characterized by one-sided tilt of the trunk or its reduced mobility to one side. We aim to advance knowledge on the abnormal posture due to impairment of dynamic balance as a consequence of stroke, and to exploit visual and proprioceptive stimulations in order to improve posture and trunk asymmetry in post-stroke patients. Finally we will evaluate efficiency of rehabilitation procedures using two different approaches: i) by recording of the centre of pressure using force plate and ii) by recording of trunk tilts using inertial sensors.
Duration: 1.8.2021 – 30.6.2025
Multi-Glu – Viac-cieľový prístup k rozličných molekulovým mechanizmom diabetických komplikácií a iných ochorení súvisiacich s toxicitou glukózy
Multi-target approach to diverse molecular mechanisms of diabetic complications and other glucose toxicity related diseases
Program: SRDA
Project leader: RNDr. Májeková Magdaléna, PhD.
Annotation: Diabetes mellitus and other diseases related to the glucose toxicity have multifactorial character comprised ofmultiple mechanisms. Besides others, the mechanisms include increased polyol pathway activity, non-enzymaticglycations of proteins, hexosamine pathway, altered protein kinase C activity, oxidation stress and impairedcalcium signaling. Targeting individual mechanisms could lead to design of new compounds – potential drugs for atreatment of diabetic complications. Our aim is to elucidate the impact and roles of individual mechanisms. In thisendeavor, we will build upon our previous results, which brought a new insight in details of polyols pathwaymechanisms by means of the study of cemtirestat and other novel compounds designed by our group.
Duration: 1.8.2021 – 30.6.2025
Fenolové látky a ich semisyntetické deriváty ako terapeutické nástroje pre ovplyvnenie stresu endoplazmatického retikula prostredníctvom SERCA púmp.
Program: VEGA
Project leader: RNDr. Lomenová Jana, PhD.
Duration: 1.1.2021 – 31.12.2024
Hyperurikémia pri rôznych komorbiditách metabolického syndrómu – mechanizmy vplyvu kyseliny močovej na endotelovú funkciu a deformabilitu erytrocytov.
Hyperuricemia in various comorbidities of the metabolic syndrome – mechanisms of the effect of uric acid on endothelial function and erythrocyte deformability.
Program: VEGA
Project leader: RNDr. Bališ Peter, PhD.
Annotation: Numerous studies have shown a significant complex relationship between increased concentration of uric acid(UA) in blood (hyperuricemia) and noncommunicable diseases, including arterial hypertension, metabolicsyndrome, diabetes mellitus and cardiovascular diseases. Nevertheless, the mechanisms by which hyperuricemialead to organ damage are not elucidated yet. Higher UA levels in blood are independent predictors of general andcardiovascular mortality. UA may have a direct negative effect on endothelial function. Therefore, we are focusingon relationship between hyperuricemia and endothelial function in macro- and microcircula. The quality ofmicrocirculation is to high extent also determined by erythrocyte properties.The main aim of the project is to bring new information about the mechanisms of hyperuricemia-inducedendothelial dysfunction in various comorbidities of the metabolic syndrome, including arterial hypertension,diabetes mellitus, dyslipidemia and obesity, with the focus on microcirculation.
Duration: 1.1.2021 – 31.12.2024
Kardioprotektívny potenciál TRP kanálov: úloha v remodelácii, zápale a vápnikovej dysregulácii
Cardioprotective potential of TRP channels: the role in remodelation, inflammation and calcium dysregulation
Program: VEGA
Project leader: MUDr. Ravingerová Táňa, DrSc., FIACS
Annotation:
Duration: 1.1.2021 – 31.12.2024
Posturálna hrozba v prostredí virtuálnej reality u ľudí so strachom z výšky
Postural threat in virtual reality in adults with height intolerance
Program: VEGA
Project leader: RNDr. Bzdúšková Diana, PhD.
Annotation: Virtual reality (VR) is suitable for evaluating postural and psychophysiological parameters in different situations and different populations. Fear of height and subsequent fall causes limitations in daily living and avoidance of any height, which represents a postural threat. A possible solution to relieve the stress and anxiety is a stance on an elevated platform in VR, which can repeatedly create a real-life experience that the subject gradually becomes accustomed to, but in safe and controlled conditions. Intervention can be enhanced before exposure to height by transcranial stimulation (tDCS) of the cerebellum, which plays a significant role in postural control. The aim of the project is to gain new knowledge about postural and psychophysiological reactivity during the postural threat in VR and to explore it immediately after tDCS. The obtained results may be beneficial for the rehabilitation of patients with balance disorders, people with height intolerance, and the elderly at risk of falls.
Duration: 1.1.2022 – 31.12.2024
SQUID magnetometria nano- a mikro častíc, nanokoloidov a nanoštruktúr v nových aplikáciách v oblasti biomedicíny a materiálového výskumu spojených s rozvojom nových meracích metód a postupov
SQUID magnetometry of nano- and microparticles, nanocolloids and nanostructures in new applications in the field of biomedicine and materials research associated with the development of new measurement methods and procedures
Program: VEGA
Project leader: RNDr. Bernátová Iveta, DrSc.
Duration: 1.1.2021 – 31.12.2024
Úloha signalizácie sprostredkovanej jadrovým faktorom NRF2 v regulácii metabolizmu železa počas stresu
Role of nuclear factor NRF2-mediated signalling in iron metabolism regulation during stress
Program: VEGA
Project leader: RNDr. Bernátová Iveta, DrSc.
Annotation: Stress is considered to be an etiological factor associated with the development of various chronic non-communicable diseases. Stress may also alter iron metabolism. Nuclear factor erythroid 2-related factor 2 (NRF2)-regulates several genes involved in iron metabolism. Despite the accelerating information on the roles of NRF2, less is known about the NRF2 signalling in iron metabolism in conditions of stress. Thus, the aim of this project is to investigate the role of NRF2 signalling in iron metabolism in conditions of acute and chronic stress in rats with genetic predisposition to hypertension. In addition, the effects of pharmacological activation of NRF2 signalling and the distinct roles of inducible and endothelial nitric oxide synthases in iron metabolism in stress conditions will be investigated. Thus, we obtain the original results about NO and NRF2-mediated regulation of iron metabolism and about involvement of altered iron metabolism in the development of cardiovascular and metabolic disorders.
Duration: 1.1.2021 – 31.12.2024
Vlastnosti erytrocytov a oxidačný stres za vybraných patológií a po podávaní antioxidantov
Program: VEGA
Project leader: RNDr. Vrbjar Norbert, CSc.
Duration: 1.1.2021 – 31.12.2024
DIAMICROBIOTA – Črevná mikrobiota a diabetická periferálna neuropatia: účinok cemtirestatu v potkaňom modely diabetu
Gut microbiota and diabetic peripheral neuropathy: effect of cemtirestat in rat models of diabetes
Program: SRDA
Project leader: Ing. Šoltésová Prnová Marta, PhD.
Duration: 1.7.2020 – 30.6.2024
Safe-MDs – In vitro hodnotenie bio-kompatibility zdravotníckych pomôcok (ZP) a inovatívnych bio-materiálov pre ZP
In vitro biocompatibility testing of medical devices (MDs) and new generation bio-materials for MDs
Program: SRDA
Project leader: Dr.rer.nat., Ing. Kanďárová Helena, ERT
Annotation: Medical devices (MDs) have an irreplaceable role in the healthcare of the 21st century. The term ‘medical device’ covers a broad spectrum of products that are crucial in diagnosis and treatment, disease prevention and improving the quality of life of people suffering from disabilities or injuries. MD must not cause adverse effects and must demonstrate bio-compatibility with the tissues in the patient’s body.Most of the MDs\’ bio-compatibility assessments are still conducted in animals. However, thanks to the advances in cell and 3D tissue engineering and due to the accelerated progress of validation of alternative methods, the MD regulations also utilize in vitro tests, as demonstrated recently by the adoption of the in vitro reconstructed human epidermis (RhE) test for intra-cutaneous testing into the ISO standard 10993-23.The presented research proposal focuses on the development of in vitro methods for biocompatibility assessment of medical devices (MDs) and innovative materials to be used as MDs polymers and that are intended for the use in the oral and vaginal cavities or on/in ocular epithelium.
Duration: 1.7.2020 – 30.6.2024
SEMSTIM – Kognitívne a mozgové mechanizmy sémantického spracovania informácií
Cognitive and brain mechanisms of semantic processing
Program: SRDA
Project leader: MUDr. Riečanský Igor, PhD.
Duration: 1.7.2020 – 30.6.2024
HNOSES – Štúdium biologických účinkov produktov H2S/NO/selénovej interakcie a molekulárne mechanizmy ich pôsobenia
Study of biological effects of H2S/NO/selenium products and molecular mechanisms of their actions
Program: SRDA
Project leader: RNDr. Čačányiová Soňa, PhD.
Annotation: Reactive sulfur (RSS), nitrogen (RNS) and selenium species (RSEs) are groups of simple chemical molecules ofradical or non-radical nature, which interact with cellular components and thereby influence various biologicalprocesses. The study of biological effects of RSS, RNS and RSeS and their mutual interactions is important for theunderstanding of their biological roles, moreover for the potential application of these species in medicine. Ourstudies of the reactive species interaction in the last 3 years showed that:- products of hydrogen sulfide (H2S) and polysulfides (H2Sn, n≥2) interaction with nitric oxide (NO) or seleniumcompounds (R-Se) significantly affect oxygen radicals concentrations, hydroperoxide cleavage, DNA damage, ratblood pressure and tension/relaxation of isolated aorta.- H2S and H2S2 interact with tetracycline antibiotics, mainly doxycycline (DOXY) and thereby produce/inhibitsuperoxide and hydroxyl radicals and induce/inhibit DNA damageThese findings imply the possibility that reactive oxygen species (ROS) and other H2S/NO/R-Se interactionproducts affect (patho)physiological functions in living organisms. In the project´s aims we will build on the previousfindings and investigate following new hypotheses:1) Do mixtures (H2Sn/R-Se, H2Sn/R-Se/NO alebo H2Sn/DOXY) produce ROS or other biologically activecompounds?2) Are these products responsible for production/inhibition of radicals, cleavage of hydroperoxides andinduction/inhibition of DNA damage?3) Do interaction products affect ferroptosis or intracellular calcium concentration in cells?4) Do these products affect rat blood pressure, arterial pulse waveform and tension of isolated arteries?The aim of this project is to investigate the chemical biology, activity and effects of the interaction products oncellular, organ and whole-organism level. These findings may contribute to the development of novel therapeuticinterventions based on the modulation of cellular redox biology.
Duration: 1.7.2020 – 30.6.2024
MIRCVD – Úloha miRNA pri vzniku a priebehu kardiovaskulárnych ochorení – nové prístupy ochrany srdca v situáciách zvýšenej produkcie reaktívnych foriem kyslíka
The role of miRNAs in the onset and progression of cardiovascular diseases – new approach to the protection of the heart in situations of increased production of reactive oxygen species
Program: SRDA
Project leader: RNDr. Kura Branislav, PhD.
Annotation: Despite progress in prevention, diagnosis and treatment, cardiovascular disease (CVD) is one of the highest morbidity and mortality rates in the world. World Health Organization statistics suggest that in 2030 approximately 23.6 million people will die of CVD, particularly from heart failure and myocardial infarction. One of the most common causes of many CVDs is excessive production of reactive oxygen species (ROS). These arise naturally in all organisms that gain energy by oxidizing substrates, but are also the result of various exogenous effects, such as radiation or air pollution. ROSs affect all types of cells in the body. By their activity, they cleave electrons from the molecules, making the surrounding molecules unstable and subsequently damaging other surrounding molecules. This damage process leads to cell apoptosis, tissue damage and pathological processes and diseases. At present, many experimental works emphasize the use of microRNAs (miRNAs) in diagnostics and potentially also in CVD therapy. miRNA is a group of short non-coding RNAs that, upon binding to a protein mRNA chain, inhibit its synthesis, greatly affecting many processes in the body. ROS production and the effect of miRNA expression are linked to the development of many CVDs, so it is important to understand the relationship between these factors. Research into new suitable substances and methods that can positively affect the effects of excessive ROS formation on the cardiovascular system can significantly improve the quality of life of cardiological patients. The aim of the project is to look for suitable substances that will prevent toxic effects of excessively formed ROS and positively affect the mechanisms that cause damage. At the same time, elucidation of the role of miRNA involvement in signaling pathways associated with the action of ROS on the development and progression of various CVDs is also be presented.
Duration: 1.7.2020 – 30.6.2024
NEISAD – Úloha neischemických adaptačných stimulov v ochrane ischemického myokardu: štúdium spúšťacích mechanizmov a bunkovej kardioprotektívnej signalizácie.
The role of non-ischemic adaptive stimuli in protection of ischemic myocardium: study of triggering mechanisms and cardioprotective cell signaling
Program: SRDA
Project leader: MUDr. Ravingerová Táňa, DrSc., FIACS
Annotation: Cardiovascular diseases, especially ischemic heart disease (IHD) as a leading cause of heart failure and mortalityworldwide, will not reduce over the coming decades despite the progress in pharmacotherapy, interventionalcardiology and surgery. It is due to aging population and longer survival after acute myocardial infarction (MI),gradual decline of its function and incidence of comorbidities (diabetes, hypertension, dyslipidemia). Experimentalstudies revealed attenuation of MI by adaptive phenomenon of ischemic “conditioning“. However, it is not usuallyapplicable in clinical medicine. In line with translation-oriented research, the project is aimed to: 1. verify theefficiency of cardioprotection induced by non-ischemic stimuli, such as motoric activity, hypoxia and non-invasiveremote “conditioning“; 2. identify triggering mechanisms and pathways of signal transduction (“survival” cascadesRISK and SAFE) to the target structures involved in heart injury reduction (mitochondrial permeability transitionVV 2019 Základný výskumAPVV-19-0540Akronym: NEISAD 06.07.2020 10:48 Strana/Page: 2pore, MPTP, nuclear PPAR receptors); 3. investigate the impact of comorbidities, age and gender on the adaptiveprocesses considering functional, structural and subcellular cardiac alterations. Special emphasis will be placed onthe role of small non-coding RNA (miRNA) regulating cell “survival” pathways and processes of apoptosis andnecroptosis associated with cell oxidative state and Ca2+ homeostasis. We will focus on disclosure of the benefitsof combination therapy: pleiotropic effects of PPAR agonists, MPTP inhibitors, coupled with noninvasive adaptiveinterventions not only under normal but also under pathological conditions (hypertension, hyperlipidemia,hyperglycemia). On animal in vivo and ex vivo models, combination of physiological, biochemical, selectedbiophysical and molecular biology methods will enable to elucidate processes of heart failing/regeneration and gainresults that may lead to development of novel/modified strategies of IHD management.
Duration: 1.7.2019 – 30.6.2024
OffRISK – Nová generácia antidepresív – dlhodobé účinky na potomstvo
Novel antidepressant therapy – long term consequencies on offspring
Program: SRDA
Project leader: RNDr. Dubovický Michal, CSc.
Annotation: Maternal depression experienced during pregnancy endangers both mother and her offspring. It may alter brain activity of offspring on multiple systemic level. Behavioral changes observed in offspring are caused not only by depression-altered maternal behavior, but also by biochemical changes in offspring brain occurring duringpregnancy and manifested in altered neuronal excitability in relevant brain regions. These alterations may differbetween male and female offspring and may recess during adolescence. Antidepressant treatment duringpregnancy may relieve maternal depression, but it may also prevent negative effects of maternal depression onoffspring. We will focus on consequences of maternal depression on mental and physical status of offspring and on possible prevention of negative consequences by suitable treatment of the mother during pregnancy. We will characterize health status of offspring on multiple systemic levels starting with whole animal level characterized by animal behavior, through altered neuronal excitability on level of neuronal networks, following with excitability of individual neurons, biochemical alterations of neuronal metabolism, up to subcellular regulation of calcium homeostasis. We will investigate health effect and underlying cellular mechanism of antidepressant mirtazapine, which is commonly used in clinics, yet mechanism of its action is still not fully understood. We will use an established model of maternal depression activated by three weeks long pregestational stress. During weaning period we will assess maternal behavior of mirtazapine-treated and mock-treated mothers. Main focus of the project will be on effects of maternal stress on second generation, i.e., on offspring of treated and untreated of depressed mothers. Further, we will differentiate effects on male and female pups.
Duration: 1.7.2020 – 28.6.2024
Centrum pre biomedicínsky výskum – BIOMEDIRES – II. etapa
Centre for biomedical research – BIOMEDIRES – II. stage
Program: EU Structural Funds Research & Development
Project leader: doc. RNDr. Pecháňová Oľga, DrSc.
Duration: 12.3.2020 – 11.3.2024
Prenatálne programovanie chorôb v dospelosti: možnosti terapie a prevencie následkov prenatálnej hypoxie u potomstva potkanov
Prenatal programming of adult diseases: treatment and prevention of outcomes of gestational hypoxia in rat offspring
Program: VEGA
Project leader: RNDr. Mach Mojmír, PhD.
Annotation: Hypoxia during pregnancy, labor or early life stage is a major determinant of neurological morbidity and mortality in the neonatal period. In the last decade the fetal origin of chronic adult diseases was proposed as the most important factor in genesis of diabetes and hypertension in adulthood. The scientists showed that malnutrition, and inadequate oxygen supply during embryofetal development may lead to the inadequate apoptosis/necrosis, and caused maldevelopment of the organs responsible for regulation blood pressure, glucose, or improper brain wiring. Although the understanding of perinatal asphyxia-related pathophysiology is gradually increasing, limited therapeutic options are available to prevent or even mitigate the devastating process that unfolds after injury. Mitochondria-targeted antioxidants (MTA) are one of the most important therapies for providing neuroprotection in cerebral ischemia. The aim of the project will be to explore the possibilities of using MTA in late gestational hypoxia model.
Duration: 1.1.2020 – 31.12.2023
Experimentálna liečba neonatálnej hypoxicko-ischemickej encefalopatie (nHIE): potenciácia hypotermickej neuroprotekcie melatonínom u novorodených potkanov
Experimental therapy of neonatal hypoxic-ischemic encephalopathy (nHIE): potentiation of hypothermic neuroprotection by melatonin in newborn rats
Program: VEGA
Project leader: RNDr. Juránek Ivo, PhD., DrSc.
Annotation: Neonatal hypoxic-ischemic encephalopathy (nHIE) is among most serious causes of mortality and morbidity in newborns. Efficacy of current nHIE treatment is rather low. Routinely used therapeutic hypothermia (HT) is only partially effective. To augment hypothermic neuroprotection, drugs like erythropoietin, anticonvulsants, antioxidants and inert gases are tested. In this project, using newborn rats, we will study possible augmentation of hypothermia effect by combining HT with melatonin (MEL)-derived antioxidants. We will assess brain damage and efficacy of each intervention by various techniques, including noninvasive in vivo MRI and MRS, histology and neurobehavioral testing. Novelty of the project lies in testing our idea that MEL-derivative possessing antioxidative properties 100 fold higher than MEL will be more effective in potentiating the hypothermic effect than MEL itself. Anticipated results may help understand better nHIE mechanisms and to propose new strategies to treat birth asphyxia effectively.
Duration: 1.1.2020 – 31.12.2023
Hodnotenie a porovnanie protizápalovej a antioxidačnej účinnosti karotenoidov in vitro a in vivo pomocou modelov chronických zápalových ochorení.
Program: VEGA
Project leader: PharmDr. Bauerová Katarína, PhD., DrSc.
Annotation:
Duration: 1.1.2020 – 31.12.2023
Hodnotenie biologickej kompatibility zdravotníckych pomôcok (ZP) a innovativnych materiálov pre výrobu ZP s využitím in vitro metód založených na 3D rekonštruovaných modeloch ľudského tkaniva.
Bio-compatibility assessment of medical devices and novel medical device materials using in vitro methods based on 3D reconstructed human tissue models.
Program: VEGA
Project leader: Dr.rer.nat., Ing. Kanďárová Helena, ERT
Duration: 1.1.2020 – 31.12.2023
Mezenterický perivaskulárny tuk a jeho špecifická úloha v regulácii črevnej cirkulácie u potkana pri rôznych režimoch príjmu potravy
Mesenteric perivascular fat and its specific role in regulation of intestinal circulation in rats with different feeding regimens
Program: VEGA
Project leader: Mgr. Zemančíková Anna, PhD.
Annotation: This project will solve questions to what extent and in which way might the different diet and feeding regimens(intermittent, ad libitum, high fat diet) influence the regulation of smooth muscle activity of rat mesenteric arteriesby perivascular fat, and which signal mechanisms participate on these processes. Besides healthy individuals,obese rats will be used in which the vascular sympathetic tone is enhanced and its activity is specificallyregulated by mesenteric adipose tissue. On isolated conduit and small mesenteric arteries, the effect ofmesenteric fat on their reactivity, biochemical processes, and function of perivascular nerves will be measured.The results of this study should be aimed to respond the question how much these processes might be involvedin ingestion/utilization of food in subjects under different dietary regimens, and subsequently in regulation of bodyweight and visceral adiposity in individuals negatively influenced by obesity.
Duration: 1.1.2021 – 31.12.2023
Podieľajú sa konexinové kanály v preťaženom srdcovom svale na extracelulárnej remodelácii?
Are connexin channels involved in extracellular matrix remodeling of overloaded heart?
Program: VEGA
Project leader: RNDr. Tribulová Narcisa, DrSc.
Annotation: Cardiac connexin (Cx) channels that are localized at the gap junctions in intercalated discs ensure electrical and molecular signals propagation among cardiomyocytes. Such direct intercellular signaling is essential for synchronized heart contraction. Cardiovascular diseases in humans as well as in animal models are accompanied by abnormal Cx43 expression and its enhanced localization to the lateral sides of the cardiomyocytes. Consequently, it deteriorates synchronized heart function and increase a risk for malignant arrhythmias. Based on general knowledge and our studies we hypothesize that laterally localized Cx43 channels might transmit signals from cardiomyocytes into extracellular space and by this way contribute to adverse extracellular matrix remodeling. Intention of the project is to reveal the possible implication of Cx43 channels in modulation of extracellular space in diseased heart. It may stimulate to search novel approaches in protection from cardiac dysfunction and arrhythmias.
Duration: 1.1.2020 – 31.12.2023
Porovnanie antidepresívnych účinkov prírodného psychoplastogénu a aktivátora mTOR v animálnom modeli depresie
Comparison of antidepressant effects of natural psychoplastogen and an mTOR activator in animal model of depression
Program: VEGA
Project leader: RNDr. Vranková Stanislava, PhD.
Annotation: Increasing prevalence of depression presents an unavoidable problem for psychiatry. Existing antidepressantsexert their effect only after several weeks of continuous treatment. In addition, their serious side effects inone-third of patients call for urgent action. Recent advances have given rise to the concept of psychoplastogens.These compounds are capable of fast structural and functional rearrangement of neural networks by targetingmechanisms previously implicated in the development of depression. Furthermore, evidence shows that theyexert potent acute and long-term positive effects. Several of them are naturally occurring compounds, such as7,8-dihydroxyflavone (7,8-DHF). The aim of our study is to investigate the effects of 7,8-DHF and NV-5138, anmTOR (mammalian target of rapamycin) activator, and their combinations, on the development of depressive-likesymptoms in animal model. Results of this project will contribute to elucidating the pathogenesis of depressionand their treatment possibilities.
Duration: 1.1.2021 – 31.12.2023
Použitie hmotnostnej spektrometrie na porovnanie glykoprofilov rôznych kmeňov potkanov v intervencii metabolických porúch
The use of mass spectrometry for comparative study of different rats strains glycoprofiles within metabolic disturbances intervention
Program: VEGA
Project leader: Ing. Brnoliaková Zuzana, PhD.
Annotation: Metabolic syndrome (MetS) defines a cluster of interrelated risk factors for diabetes mellitus. Glycobiology ishelping in search for biomarkers of severe diseases, the bioanalytical metods were patented. We hypothesize:the glycomic profiling of blood sera has the potential in MetS diagnostics. The goals are to acquire glycomicprofiles, by means of mass spectrometry, derived from blood sera of different rats strains; to characterize theircomposition; to correlate with pathophysiology; to evaluate the differences with respect to the glycosylationchanges (sialylation, fucosylation). In vivo: to realize the study with nutritional intervention; to evaluate the effectof allimentary habits preferences on the metabolic condition. In vitro: to investigate the impact of key mechanismsof MetS in association with cellular glycoprofile induced changes. As the output: might be the model glycomic toolfor basic research appointed to test therap. approaches with perspespective for clinical researchrecommendations.
Duration: 1.1.2021 – 31.12.2023
Prepojenie niektorých foriem bunkovej smrti nekrotického fenotypu: signalizácia a multicieľový nástroj pre zmiernenie poškodenia srdca v dôsledku ischémie?
Program: VEGA
Project leader: MUDr. Ravingerová Táňa, DrSc., FIACS
Annotation:
Duration: 1.1.2020 – 31.12.2023
SVBENMKVS – Skúmanie vplyvu bakteriálneho endotoxínu na mechanosenzorický komplex v srdci.
Investigation of endotoxin effects on mechanosensoric complex in the heart of normotensive rats.
Program: VEGA
Project leader: RNDr. Okruhlicová Ľudmila, CSc.
Annotation:
Duration: 1.12.2020 – 31.12.2023
Štúdium nových mechanizmov kardioprotekcie voči ischemicko-reperfúznemu poškodeniu srdca: úloha extracelulárnych vezikúl, nekódujúcich RNA a vplyv metabolických komorbidít na tieto mechanizmy
Study of new mechanisms of cardioprotection against ischemia-reperfusion injury of the heart: role of extracellular vesicles, non-coding RNAs and impact of metabolic co-morbidities on these mechanisms
Program: VEGA
Project leader: doc. RNDr. Barteková Monika, PhD.
Annotation: Ischemic heart disease and myocardial infarction represent major diseases associated with ischemia-reperfusion(I/R) injury of the heart. Despite several powerful cardioprotective interventions against I/R injury includingendogenous (e.g. ischemic conditioning) as well as exogenous ones including treatment with natural antioxidants,have been proposed, molecular mechanisms of cardioprotection are not fully clarified so far; moreover, there areserious translational gaps in transferring cardioprotective interventions into clinics due to comorbidities present inreal patients suffering from cardiac I/R injury. The aim of the present project is to uncover the role of extracellularvesicles as new players in cardioprotection, to identify particular non-coding RNAs involved in cardioprotection,and to explore the effect of metabolic co-morbidities on molecular mechanisms and efficiency of cardioprotection,altogether in the sake of effective transfer of experimental knowledge to human personalized medicine.
Duration: 1.1.2020 – 31.12.2023
Úloha makroautofágie a autofágie sprostredkovanej šaperónmi (CMA) v odpovediach a v adaptácii živočíšnych buniek na účinky vyvolané pôsobením doxorubicínu
The role of macroautophagy and chaperone-mediated autophagy (CMA) in the responses and adaptation of animal cells to doxorubicin-induced effects
Program: VEGA
Project leader: RNDr. Barančík Miroslav, DrSc.
Annotation: The project is focused on characterization of the role of macroautophagy and chaperone-mediated autophagy (CMA) in molecular mechanisms involved in responses of animal cells to the effects of doxorubicin (DOX). The aim is also to study the involvement of intracellular (protein kinases) and redox (Nrf2) signaling in regulation of both types of autophagy after DOX effects. The effects of flavonoid quercetin and Nrf2 pathway activator sulphoraphane on modulation of autophagy and autophagy-related signaling after effects of DOX will also be studied.
Duration: 1.1.2021 – 31.12.2023
Vplyv starnutia a hypertenzie na experimentálny infarkt myokardu
The effect of aging and hypertension on experimental myocardial infarction
Program: VEGA
Project leader: RNDr. Cebová Martina, PhD.
Annotation: Myocardial infarction is a serious cardiovascular disease associated with cardiac remodeling as a consequenceof ischemia. Hypertension and aging aggravate the consequences of heart attack by the formation of oxidativeand inflammatory mediators in the heart. Mereover, reperfusion after ischemia creates additional oxidative stresswith a negative effect on myocardial tissue. To monitor the signaling molecules that can block or reverse thepathological process of infarction in hypertension is an important hypothesis for successful treatment ofmyocardial infarction. Therefore, our goal will be to exmine the effect of hypertension and aging on myocardialinfarction and to analyze the effect of nitric oxide production, free oxygen radicals, and pleiotropic transcriptionfactor Nrf2. In particular, the activation of Nrf2 and its target genes in elderly individuals may provide a novelmechanism of protection the myocardium from pathological cardiac remodeling.
Duration: 1.1.2020 – 31.12.2023
Výskum prírodných látok s terapeutickým potenciálom v humánnej medicíne: komplexná analýza, biologické účinky a štúdium synergie.
Program: VEGA
Project leader: Ing. Račková Lucia, PhD.
Annotation: Research work in the field of natural sources of antimicrobial active substances from the last two decades confirms the strong potential of natural substances and extracts, both in the eradication of resistant bacteria and fungi, but also in the prevention of biofilm formation and its destruction. The aim of this project is to test the biological activities of selected plant extracts, their secondary metabolites and their semisynthetic derivatives as potential antimicrobial and antibiofilm, as well as antioxidant, antiphlogistic and immunomodulatory agents. At the same time to exclude their cytotoxic potential on human cells in vitro and to evaluate the fingerprint of plant extracts by modern analytical methods. The target site for the action of these substances should be microbes colonizing skin infections (especially poorly healing, burns, surgical / postoperative wounds) and infections of the oral mucosa (especially the root canals of devital teeth and periradicular tissues). Another aim is to create a combination of active substances / extracts (synergistically acting), which will be adjusted to a gel base, which will be enriched with high-purity micronized beta-glucan in order to eradicate microbes on the skin and mucosa and promote tissue regeneration.
Duration: 1.1.2020 – 31.12.2023
TOXINOVAGE – Inovatívne prístupy v toxikológii starnutia
Innovative approaches in toxicology of ageing
Program: SRDA
Project leader: Ing. Račková Lucia, PhD.
Duration: 1.7.2019 – 30.6.2023
Štúdium štruktúrnych zmien komplexných glykokonjugátov v procese dedičných metabolických a civilizačných ochorení
The study of structural changes of complex glycoconjugates in the proces of inherited metabolic and civilization diseases
Program:
Project leader: Ing. Brnoliaková Zuzana, PhD.
Annotation:
Duration: 1.3.2021 – 30.6.2023
Úloha matrixových metaloproteináz v patofyziológii ochorení kardiovaskulárneho systému a ich vzťah k bunkovej redoxnej signalizácii.
The role of matrix metalloproteinases in pathophysiology of cardiovascular system diseases and their relation to cellular redox signaling.
Program: SRDA
Project leader: RNDr. Barančík Miroslav, DrSc.
Annotation: The aim of the project is to characterize the role of matrix metalloproteinases and Nrf2 signaling in responses of cardiac cells to pathological conditions associated with effects of anthracycline doxorubicin and in conditions of diabetes. The goal will also be to determine the effects of Nrf2 activator sulforaphane and flavonoid quercetin on activation of responses mediated by Nrf2 pathway, on modulation of cellular injury, and on changes in activity/function of matrix metalloproteinases. To clarify the mechanisms connected with Nrf2 signaling, the intracellular (protein kinase pathways) and intercellular (connexin-43) signaling as well as regulation of enzymes involved in protection of cells against stress pathological conditions will be determined.
Duration: 1.7.2019 – 30.6.2023
BIOVID-19 – Vývoj biomodelov pre zlepšenie hodnotenia účinnosti liekov a látok, ktoré majú potenciál pri liečbe COVID-19 (BIOVID-19)
Development of biomodels to improve efficiency assessment of drugs and substances that have the potential to treat COVID-19 (BIOVID-19)
Program:
Project leader: doc. RNDr. Pecháňová Oľga, DrSc.
Annotation: The aim of the project is to develop an animal model to improve the evaluation of the effectiveness of drugs identified as having potential in the treatment of COVID-19. We will use the current knowledge about this disease, but mainly the findings obtained from samples of patients who died in direct connection with COVID-19 infection. We will currently test the most suitable treatment on the developed model.
Project web page: http://www.esif-cemsav.sk/
Duration: 9.6.2021 – 30.6.2023
Vývoj produktov modifikáciou prírodných látok a štúdium ich multimodálnych účinkov na ochorenie COVID-19
Development of products by modification of natural compounds and study of their multi-modal effects onCOVID-19 disease
Program:
Project leader: RNDr. Májeková Magdaléna, PhD.
Duration: 1.7.2021 – 30.6.2023
Experimentálna štúdia pôsobenia materskej depresie a antidepresívnej liečby počas gravidity a laktácie na zdravie matky a vývin potomstva.
Program: VEGA
Project leader: RNDr. Dubovický Michal, CSc.
Annotation:
Duration: 1.1.2019 – 31.12.2022
Experimentálny infarkt myokardu: príspevok hypertenzie a obezity, účinok inhibítora toll-like receptorov.
Program: VEGA
Project leader: doc. RNDr. Pecháňová Oľga, DrSc.
Duration: 1.1.2019 – 31.12.2022
Kognitívne a neurofyziologické determinanty sémantickej kognície
Cognitive and neurophysiological determinants of semantic cognition
Program: VEGA
Project leader: Mgr. Marko Martin, PhD.
Annotation: Semantic system creates and structures knowledge that guides adaptive cognition and behavior. The ability to access and use relevant semantic information is underpinned by a number of neurocognitive mechanisms, which are poorly understood. Our research aim is to investigate the cognitive systems and mechanisms that regulate the retrieval of information from semantic memory. For this purpose, we will use systematic manipulation of cognitive load and non-invasive transcranial electrical stimulation (tES) of the prefrontal brain cortex. Using these experimental approaches, we will inspect the role of executive control in semantic retrieval and provide a detailed description of the fundamental cognitive and neurophysiological determinants of semantic retrieval functions.
Project web page: https://www.researchgate.net/project/Cognitive-and-neurophysiological-determinants-of-semantic-cognition
Duration: 1.1.2020 – 31.12.2022
Modulácia dysregulácie extracelulárnej matrix a medzibunkovej komunikácie ako protekcia srdcového svalu pred jeho funkčným zlyhaním
Modulation of dysregulation of extracellular matrix and intercellular communication as a heart protection from its functional failure
Program: VEGA
Project leader: RNDr. Szeiffová Bačová Barbara, PhD.
Annotation: Cardiovascular diseases are accompanied by extracellular matrix remodeling and fibrosis associated with impaired myocardial gap junction communication, what subsequently results in the development of heart failure and malignant arrhythmias. Cardiac fibrosis is one of the major problems in medicine with no effective treatment. We aimed in this project to characterize key factors involved in profibrotic signaling in rats with hypertension, altered thyroid status, post-infarction injury and to examine the possibilities of pharmacological and non-pharmacological modulation of these profibrotic factors. This approach should reveal key signaling pathways and proteins whose modulation could reverse or stop fibrosis process and then improve intercellular communication in the myocardium. Project results should contribute to new knowledge potentially usable in clinical practice as well.
Duration: 1.1.2019 – 31.12.2022
PROTEKCIA KARDIOVASKULÁRNEHO SYSTÉMU PRI EXPERIMENTÁLNEJ HYPERTENZII A ZLYHANÍ SRDCA DUÁLNOU INHIBÍCIOU NEPRILYZÍNU A AT1 RECEPTOROV PRE ANGIOTENZÍN II: POROVNANIE S ACE-INHIBÍCIOU A MELATONÍNOM
Program: VEGA
Project leader: doc. RNDr. Pecháňová Oľga, DrSc.
Duration: 1.1.2019 – 31.12.2022
TraiN-SafeMDs – Školiaca sieť zameraná na zvýšenie bezpečnosti zdravotníckych pomôcok – fokus na ústnu dutinu
Training Network for improving of safety of medical devices – focus on oral cavity
Program: SRDA
Project leader: Dr.rer.nat., Ing. Kanďárová Helena, ERT
Annotation: Medical devices (MDs) have irreplaceable role in modern healthcare. The term ‘medical device’ covers a broad spectrum of products that are crucial in diagnosis and treatment, disease prevention and improving the quality of life of people suffering from disabilities or injuries. MDs used in the oral cavity are usually those helping in the treatment of aphthae or canker sores irritations and lesions of the oral mucosa by forming a barrier that adheres to the oral mucosa and promotes healing. Dental materials and dental prosthetic devices are also an important group of MDs with apparent contact with oral mucosa. Most of the MDs bio-compatibility assessments is still conducted in animals. However, thanks to the advances in cell and 3D tissue engineering and due to the accelerated progress in validation of alternative methods, the MD regulations are also in vitro tests, as demonstrated recently by the adoption of the in vitro reconstructed epidermis test for intra-cutaneous testing into the ISO standard 10993-23 (Kandarova et al.,/DeJong et al., 2018). Biocompatibility testing of MDs is based on the toxicity assessment of extracts from MDs, that are in fact highly diluted solutions of potential irritants. Therefore any already validated in vitro tests and prediction models must be fine-tuned to achieve different levels of sensitivity for this specific type of materials.The proposed project builds on the practical experiences gained in the validation study for intra-cutaneous testing of MDs in which the research teams from Slovakia and Czech republic participated between 2012-2018. The current project will use 3D reconstructed tissues of oral/buccal epithelia and cell cultures with the origin in oral cavity with the aim to develop highly sensitive testing strategy for local tolerance testing in vitro. The project alsoaims into the training of PhD students and early career scientist in the use of in vitro methods for the safety assessment of MDs.
Project web page: medicaldevicessafety.com
Duration: 1.3.2020 – 31.12.2022
Účinky prírodných a syntetických zlúčenín pri oxidačnom poškodení biomakromolekúl. Pro- a antioxidačné mechanizmy.
Effects of natural and synthetic compounds on oxidative damage of biomacromolecules. Pro-oxidative and antioxidative mechanisms.
Program: VEGA
Project leader: RNDr. Valachová Katarína , PhD.
Annotation:
Duration: 1.1.2019 – 31.12.2022
Účinok bakteriálneho endotoxínu na komunikačné spojenia ciev srdca za podmienok hypertenzie.
Program: VEGA
Project leader: Ing. Frimmel Karel, PhD.
Duration: 1.1.2019 – 31.12.2022
Vazoaktívne účinky sulfidovej signalizácie a jej interakcia s oxidom dusnatým v rôznych animálnych modeloch metabolického syndrómu
Vazoactive effects of hydrogen sulphide signalling pathway and its interaction with nitric oxide in different animal models of metabolic syndrome
Program: VEGA
Project leader: Mgr. Berényiová Andrea, PhD.
Annotation: Nitric oxide (NO) and hydrogen sulphide (H2S) are signalling molecules involved into the regulation of the arterial tone. The synthesis of both has been shown in arterial wall, moreover their contribution in physiological (relaxation of arterial smooth muscle cells) and pathophysiological processes (hypertension, diabetes mellitus, atherosclerosis) have been already proved. Metabolic syndrome (MS) is a group of abnormalities including obesity, hypertension, hyperlipidemia which that together increase the risk of developing cardiovascular disease. Studies have characterised H2S signalisation and NO-H2S interaction especially in normotensive rats, information about their role in experimental hypertension are just limited and about their engagement into the etiopathogenesis of metabolic syndrome is totally missing. The main goal of this project is to describe the vasomotoric role of NO and H2S in different models of MS: induced by high-fructose diet, by high-fat diet in normotension and primary hypertension.
Duration: 1.1.2019 – 31.12.2022
Vplyv fruktózovej diéty v experimentálnych modeloch metabolického syndrómu a u zdravých jedincov: návrh účinnej farmakologickej liečby
Effect of fructose diet in experimental models of metabolic syndrome and in healthy subjects: proposal of effective pharmacological treatment
Program: VEGA
Project leader: RNDr. Gáspárová Zdenka, PhD.
Annotation: The project will contribute to the knowledge about etiopathogenesis of metabolic syndrome (MetS). It extend the current project, where we study the impact of high-fat and high-fat-high-fructose diet on hypertriacylglycerolemic(HTG) rats. Chronic diseases such as MetS are generally multifactorial. Thus in their origin and development play a role not only environment (diet, physical activity, stress) but also genetic predisposition. In the new project, we will examine effect of fructose diet (FD) on various animal models (spontaneously hypertensive, HTG, Zucker obese/nonobese and Wistar healthy rats) and find which main risk factor of MetS together with FD cause the most serious damage. We will test the effect of the prospective pyridoindole SMe1EC2 and omega-3 fatty acids on the established model. By combining of these drugs, we expect increased effect on a number of risk factors of cardiovascular and cerebrovascular diseases without causing adverse effects, thus a proposal for a new more effective treatment.
Duration: 1.1.2019 – 31.12.2022
Terapia KVO – Vplyv terapie na redoxnú reguláciu, biochemické markery a bunkovú signalizáciu vekovo-závislých kardiovaskulárnych a neurodegeneratívnych ochorení.
Effect of therapy on redox regulation, biochemical markers and cell signaling of age-dependent cardiovascular and neurodegenerative diseases.
Program: VEGA
Project leader: doc. RNDr. Dovinová Ima, PhD.
Annotation: In cardiovascular damage, oxidative stress is triggered by an increase in oxidative stress, affecting changes in the activities of SOD / NOS proteins, biochemical markers, metabolites, as well as redox regulation of SERCA Ca2 + -ATPases. Oxidative stress is a regulated antioxidant and detoxification response by activating the transcription factor Nrf2.The nuclear receptor and nutritional factor PPAR gamma is another regulator of signaling pathways that is positively linked to the regulation of Nrf2. PPAR gamma nuclear receptor agonists play an important role in the regulation of cardiovascular and hypertensive diseases.
Duration: 1.1.2020 – 31.12.2022